Semax Leitfaden & Dosierungstabelle

What is Semax?

Semax is a synthetic heptapeptide — a tiny chain of seven amino acids — originally designed as an analog of a fragment of ACTH, the body's natural adrenocorticotropic hormone.^[1] Its full sequence is Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP).^[5] Russian scientists developed it decades ago, and it has been studied primarily for its nootropic (cognition-enhancing) and neuroprotective properties. In Russia, it has been used clinically for stroke treatment, but everywhere else it remains a research compound — not approved for human use outside that context.

Because it mimics part of ACTH but adds a special Pro-Gly-Pro tail, Semax behaves differently from plain ACTH — it appears to act on the brain without the strong hormonal side effects you'd expect from full ACTH.^[1]

How Semax Works

Think of Semax like a master key that fits several different locks in the brain and nervous system. Here are the main mechanisms researchers have identified:

• Neurotrophins: Neurotrophins are the brain's own growth factors — proteins that keep neurons alive and help them form new connections. Studies in rats show that Semax can switch on the genes that produce BDNF, NGF, and other neurotrophins, especially after brain injury.^[6] Think of it as turning up the volume on the brain's own repair signals.
• Monoamine neurotransmitters: Semax has been shown to influence dopamine and serotonin levels in the brain — the chemical messengers tied to mood, motivation, and learning.^[3]
• Opioid receptors: Recent research found that Semax targets the μ-opioid receptor, which then triggers a chain of events involving a protein called USP18 that reduces harmful inflammation inside cells.^[1]
• Copper chelation: Semax binds tightly to copper ions (Cu²⁺). This turns out to be important because copper can supercharge the toxicity of amyloid-beta (Aβ), the protein that builds up in Alzheimer's disease. By grabbing that copper, Semax can slow down harmful amyloid clumping and reduce the toxic molecules (reactive oxygen species, or ROS) that copper-Aβ complexes generate.^[4][5]
• BDNF and neuroplasticity: Semax has also been noted to enhance BDNF signaling pathways relevant to neuroplasticity — the brain's ability to rewire itself.^[2]

What the Research Shows

Most Semax research is preclinical, meaning it's been done in cells and animals, not yet in large human trials. Here's what the studies tell us:

Neuroprotection after stroke

In rats with permanent blockage of the middle cerebral artery (a model of stroke), Semax rapidly boosted the transcription of neurotrophins like BDNF, NGF, and NT-3 in the injured brain cortex — and it did so selectively in the damaged tissue, not broadly everywhere.^[6] This selectivity is considered a good sign because it suggests Semax turns on repair mechanisms where they're actually needed.

Spinal cord injury recovery

A 2025 study in female mice found that Semax improved functional recovery after spinal cord injury. It worked by targeting μ-opioid receptors, reducing oxidative stress, and preventing a form of cell death called pyroptosis — essentially stopping runaway inflammation from destroying more neurons.^[1] This research also highlighted a novel pathway involving a deubiquitinating enzyme called USP18.

Alzheimer's-related amyloid and copper

Two studies from the same Italian research group showed that Semax can strip copper away from amyloid-beta complexes, slow down the formation of toxic amyloid fibers, and protect human neuronal cells (SH-SY5Y cells) from oxidative damage in lab dishes.^[4][5] These findings position Semax as a potentially interesting compound to study in the context of Alzheimer's disease, though no human trials have tested this.

Behavior and neurochemistry

In a rat study examining the aftermath of early-life SSRI exposure, Semax reduced anxiety-like behavior, improved learning performance in a maze task, and helped normalize monoamine (dopamine and serotonin) levels in the brain.^[3] This is the study behind the preclinical doses shown in the dosage chart on this page.

Orthopaedic and neuroplasticity context

A recent review of therapeutic peptides in orthopaedics highlighted Semax alongside other neuroactive peptides for its ability to enhance BDNF and support neuroplasticity — properties relevant not just to cognition but potentially to neuromuscular recovery.^[2]

What Semax Is Being Studied For

• Cognitive enhancement and nootropic effects
• Neuroprotection after stroke or brain injury
• Spinal cord injury recovery^[1]
• Alzheimer's disease-related amyloid toxicity^[4][5]
• Anxiety and stress-related behavioral changes^[3]
• Neuroplasticity and neurotrophic support^[2][6]

How Semax Is Dosed in Research

Dosing in animal studies varies widely depending on the research goal. The preclinical studies summarized here used, for example, a single 0.15 mg dose to study dopaminergic and serotonergic neurochemistry, and a 60 mcg once-daily regimen to observe antidepressant-like and antistress effects in chronic unpredictable stress models.^[3] These are animal research doses only — they cannot be directly applied to humans. See the dosage chart on this page for a full breakdown of doses used in referenced studies, and use the calculator to explore weight-based conversions for preclinical reference purposes.

Mixing and Storing Semax

Semax typically arrives as a lyophilized (freeze-dried) powder in a sealed vial. To reconstitute it for research use, bacteriostatic water or sterile saline is drawn up with a clean syringe and injected slowly down the side of the vial — never shaken, just gently swirled — to avoid damaging the peptide structure. Once mixed, the solution should be stored in a refrigerator (around 2–8 °C) and used within a few weeks. For longer storage of the dry powder, a freezer is preferred. Always keep vials away from direct light, as peptides can degrade when exposed to UV. Label each vial with the reconstitution date so you can track freshness accurately.

Sources

1. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. — British journal of pharmacology, 2025. PMID 40692165.
2. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026. PMID 41490200.
3. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. — Neuropeptides, 2021. PMID 33418449.
4. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. — ACS chemical neuroscience, 2022. PMID 35080861.
5. Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing. — Bioinorganic chemistry and applications, 2025. PMID 40496623.
6. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. — Cellular and molecular neurobiology, 2010. PMID 19633950.